Correction To: Castration-Resistant Prostate Cancer Patients Who Had Poor Response on First Androgen Deprivation Therapy Would Obtain Certain Clinical Benefit From Early Docetaxel Administration

International Journal of Clinical Oncology - Japan

doi 10.1007/s10147-019-01395-0